A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome
Authors:
- L JacksonLJL Jackson
- A TingATA Ting
- S MckaySMS Mckay
- P GaleaPGP Galea
- C SkeochCSC Skeoch
Open Access
- 1 July 2004
- journal article
- clinical trial
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 89 (4) , F300-F304
Abstract
Background: The incidence of neonatal abstinence syndrome (NAS) has increased 10-fold over the last decade in Glasgow. In the Princess Royal Maternity Hospital, it now accounts for 17% of special care baby unit (SCBU) admissions. Objective: To compare opiate replacement therapy (morphine sulphate) with the present standard treatment (phenobarbitone) for management of NAS. The primary study end point was duration of pharmaceutical treatment. Secondary end points were the requirement for additional drugs and the requirement for SCBU admission. Design: Double blind, randomised controlled clinical trial. Methods: Differential diagnoses were excluded, and two consecutive Lipsitz scores > 4 defined NAS requiring treatment. Infants were randomised to receive morphine sulphate or phenobarbitone. Treatments were identical in appearance, odour, and volume. Increments, decrements, and discontinuation of treatments were protocol driven. Results: Seventy five infants participated. All mothers received opiate replacement therapy (methadone) during pregnancy and most used other drugs (n = 62, 83%). No significant difference in maternal drug use patterns was observed between treatment groups. Median treatment duration was four days shorter with opiate replacement (8 v 12 days, Mann-Whitney U test, p = 0.02). Phenobarbitone treated infants tended to require second line treatment (47% v 35%, χ2 test, p = 0.11) and SCBU admission (62% v 30%, χ2 test, p = 0.04) more often. Conclusions: Opiate replacement therapy appears to be superior for management of symptomatic NAS when maternal opiate use is prevalent. The shorter treatment duration and lower requirement for higher intensity nursing may have significant cost implications. Tailoring NAS treatment to local maternal drug use may result in similar benefits.Keywords
This publication has 25 references indexed in Scilit:
- Opiate treatment for opiate withdrawal in newborn infants2002
- Sedatives for opiate withdrawal in newborn infants2002
- Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysisThe Journal of Pediatrics, 2001
- Substance misuse in early pregnancy and relationship to fetal outcomeEuropean Journal of Pediatrics, 1999
- The Neonatal Narcotic Withdrawal Index: A Device for the Improvement of Care in the Abstinence SyndromeThe American Journal of Drug and Alcohol Abuse, 1981
- Management of neonatal narcotic abstinence utilizing a phenobarbital loading dose method.1979
- Neonatal narcotic drug withdrawal syndrome.1978
- Observation and treatment of neonatal narcotic withdrawalAmerican Journal of Obstetrics and Gynecology, 1977
- A Proposed Narcotic Withdrawal Score for Use with Newborn InfantsClinical Pediatrics, 1975
- Neonatal abstinence syndrome: assessment and management.1975